Compass Q2: Tovecimig ORR Reaches 18%, FDA Feedback Looms, Cash Runway into 2028
CMPX sits 20% above its 52-week low of $1.61.
Summary
Compass Therapeutics reported Q2 2026 financials and a pipeline update. The final ORR for lead asset tovecimig improved to 18.0% (p=0.0228) in biliary tract cancer, with FDA feedback expected this quarter and a potential BLA filing later this year. Cash of $180M funds operations into 2028.
Key Events · Earnings and Guidance · CMPX
-
Tovecimig Final ORR 18.0%
The final overall response rate for tovecimig in biliary tract cancer improved to 18.0% (20/111 patients), with a p-value of 0.0228 versus paclitaxel alone (5.3% ORR). One additional patient was adjudicated as a partial response by BICR.
-
FDA Feedback Expected Q3 2026
Feedback from the FDA on the COMPANION-002 Phase 2/3 data is expected this quarter, ahead of a potential BLA filing later this year. Tovecimig data will also be presented at ESMO in October 2026.
-
Cash Runway into 2028
Cash and marketable securities totaled $180 million as of June 30, 2026, down from $209 million at year-end 2025. Net cash used in operations was $32 million in H1 2026, partially offset by $3 million from financing activities.
-
Pipeline Progress Across Four Programs
CTX-8371 Phase 1 cohort expansions are enrolling in TNBC, NSCLC, and Hodgkin lymphoma (data Q4 2026). CTX-10726 Phase 1 has dosed its first patients (initial data Q4 2026). CTX-471 Phase 2 in NCAM-expressing tumors is set to start Q3 2026.
Analysis · CMPX · Life Sciences
Compass Therapeutics delivered Q2 2026 results alongside a pivotal clinical update: the final overall response rate for lead asset tovecimig in biliary tract cancer climbed to 18.0% (p=0.0228), reinforcing the case for a BLA filing later this year. With FDA feedback expected this quarter, the coming weeks are critical for the stock. Meanwhile, three other programs are enrolling or about to start, and $180 million in cash extends the runway into 2028, easing near-term dilution concerns. The convergence of a maturing pivotal dataset, an imminent regulatory catalyst, and a solid balance sheet makes this a high-impact update.
At the time of this filing, CMPX was trading at $1.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $340.4M. The 52-week trading range was $1.61 to $6.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.